CTKB
Cytek Biosciences Inc
NASDAQ: CTKB · HEALTHCARE · MEDICAL DEVICES
$4.56
+2.70% today
Updated 2026-04-30
Market cap
$565.62M
P/E ratio
—
P/S ratio
2.81x
EPS (TTM)
$-0.52
Dividend yield
—
52W range
$2 – $6
Volume
0.7M
WallStSmart proprietary scores
41
out of 100
Grade: D
Sell
Investment rating
7.3
Growth
B+8.5
Quality
A2.0
Profitability
F6.7
Valuation
B3/9
Piotroski F-Score
Weak
3.2
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$6.00
+31.58%
12-Month target
—
—
Intrinsic (DCF)
$8.94
Margin of safety
+51.23%
1 Strong Buy1 Buy3 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.19 — safe zone
+ 51.23% below intrinsic value
+ Debt/equity 0.09x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at -33.00%
- Negative free cash flow $-1.77M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $164.04M | $193.01M | $200.45M | $201.49M | $201.49M |
| Net income | $2.58M | $-12.15M | $-6.02M | $-66.54M | $-44.08M |
| EPS | — | — | — | — | $-0.52 |
| Free cash flow | $-22.10M | $454000.00 | $21.85M | $-8.77M | $-1.77M |
| Profit margin | 1.57% | -6.29% | -3.00% | -33.02% | -33.00% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-13 | YAN, MING | Sale | 1,176,000 | — |
| 2026-03-10 | YAN, MING | Buy | 227,535 | — |
| 2026-03-10 | YAN, MING | Sale | 9,817 | — |
Peer comparison
Smart narrative
Cytek Biosciences Inc trades at $4.56. Our Smart Value Score of 41/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.19, it sits in the safe zone. TTM revenue stands at $201.49M. with profit margins at -33.00%. Our DCF model estimates intrinsic value at $8.94.
Frequently asked questions
What is Cytek Biosciences Inc's stock price?
Cytek Biosciences Inc (CTKB) trades at $4.56.
Is Cytek Biosciences Inc overvalued?
Smart Value Score 41/100 (Grade D, Sell). DCF value $8.94.
What is the price target of Cytek Biosciences Inc (CTKB)?
The analyst target price is $6.00, representing +31.6% upside from the current price of $4.56.
What is the intrinsic value of Cytek Biosciences Inc (CTKB)?
Based on our DCF model, intrinsic value is $8.94, a +51.2% margin of safety versus $4.56.
What is Cytek Biosciences Inc's revenue?
TTM revenue is $201.49M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
3.19 — safe zone.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.81x
ROE-18.00%
Beta1.28
50D MA$4.42
200D MA$4.41
Shares out0.13B
Float0.10B
Short ratio—
Avg volume0.7M
Performance
1 week+3.64%
1 month+1.79%
3 months-8.80%
YTD-9.70%
1 year—
3 years—
5 years—